Where do NewAmsterdam Pharma Company's ratios come from?

Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Profitability
Operating margin	-1,002.9%-616pp	-386.9%+912pp	-1,298.6%-1,295pp	-3.5%—
Net margin	-905.7%-375pp	-530.3%+726pp	-1,255.8%-1,234pp	-22%—
EBITDA margin	-1,001.9%-615pp	-386.7%+912pp	-1,298.2%-1,295pp	-3.5%—
Free cash flow margin	-657.8%-308pp	-349.5%+653pp	-1,002.4%-1,013pp	10.2%—
Returns
Return on equity	-28.3%+17.9pp	-46.2%+3.1pp	-49.3%—	——
Return on assets	-24.9%+14.9pp	-39.9%+3.0pp	-42.9%—	——
Efficiency
Asset turnover	0×0.0×	0.1×0.0×	0×—	——
Liquidity
Current ratio	7.9×-0.2×	8.1×+1.1×	7×-6.3×	13.3×—
Quick ratio	7.9×-0.2×	8.1×+1.1×	7×-6.3×	13.3×—
Cash ratio	5.7×-1.5×	7.2×+0.4×	6.8×-6.1×	13×—
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×—
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×—
Valuation
Market capitalization	$3.98B+44.6%	$2.75B+174%	$1.01B+2.5%	$980.85M+11.8%
Enterprise value	$3.49B+76.2%	$1.98B+198%	$664.75M+29.5%	$513.24M—
Price / sales	176.8×+116×	60.4×-11.0×	71.3×+61.8×	9.6×—
Price / book	5.8×+2.2×	3.6×+0.1×	3.5×+1.2×	2.3×—
EV / sales	155×+112×	43.5×-3.7×	47.2×+42.2×	5×—
Free cash flow yield	-3.7%+2.1pp	-5.8%+8.3pp	-14.1%-15.1pp	1.1%+4.4pp
Earnings yield	-5.1%+3.7pp	-8.8%+8.8pp	-17.6%-15.3pp	-2.3%+2.5pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do NewAmsterdam Pharma Company's ratios come from?: Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.